Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: Lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 793-795

  Roccatello, Dario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; LUPUS ANTICOAGULANT; RITUXIMAB;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CANCER INCIDENCE; CAPILLAROSCOPY; CELL CLONE; CELL PROLIFERATION; COMMON VARIABLE IMMUNODEFICIENCY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HUMAN; HYPERSENSITIVITY; IMMUNE MEDIATED INJURY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; NAILFOLD VIDEOCAPILLAROSCOPY; NONHODGKIN LYMPHOMA; PATIENT CARE; PREDICTIVE VALUE; QUALITY OF LIFE; RARE DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; THROMBOPHILIA;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNE SYSTEM DISEASES; RARE DISEASES;

EID: 84878558504     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.002     Document Type: Editorial

References (44)

1. Chapel H., Lucas M., Lee M., Bjorkander J., Webster D., Grimbacher B., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112(2):277-286. [Lug 15].
2. Baldovino S., Montin D., Martino S., Sciascia S., Menegatti E., Roccatello D. Common variable immunodeficiency: Crossroads between infections, inflammation and autoimmunity. Autoimmun Rev 2013, 12(8):796-801.
3. Dreyfus D.H. Autoimmune disease: a role for new anti-viral therapies. Autoimmun Rev 2011, 11(2):88-97.
4. Tomer Y., Sherer Y., Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review). Oncol Rep 1998, 5:753-761.
5. Tarella C., Gueli A., Ruella M., Cignetti A. Lymphocyte transformation and autoimmune disorders. Autoimmun Rev Mar 2013, 12(8):802-813.
6. Tarella C., Zanni M., Magni M., Benedetti F., Patti C., Barbui T., et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative Nei Linfomi survey. J Clin Oncol 2008, 26:3166-3175.
7. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg 2009, 6:13-19.
8. Sciascia S., Ceberio L., Garcia-Fernandez C., Roccatello D., Karim Y., Cuadrado M.J. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 2012 Dec, 12(2):157-163.
9. Marasso S.L., Giuri E., Canavese G., Castagna R., Quaglio M., Ferrante I., et al. A multilevel lab on chip platform for DNA analysis. Biomed Microdevices 2011, 13:19-27.
10. Menegatti E., Berardi D., Messina M., Ferrante I., Giachino O., Spagnolo B., et al. Lab-on-chip. Emerging analytical platforms for immune mediated diseases. Autoimmun Rev 2012 Dec 3, [Epub ahead of print].
11. Galluccio F., Matucci-Cerinic M. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev Mar 2011, 10(5):241-243.
12. Chighizola C., Shoenfeld Y., Meroni P.L. Systemic sclerosis. Introduction. Autoimmun Rev Mar 2011, 10(5):239-240.
13. Rossi D., Russo A., Manna E., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2012 Dec 4, [Epub ahead of print].
14. Bazzan M., Vaccarino A., Stella S., Bertero M.T., Carignola R., Montaruli B., et al. Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont cohort. Autoimmun Rev 2013, 12(8):826-831.
15. Pengo V., Ruiz-Irastorza G., Denas G., Andreoli L., Khamashta M., Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome. "PROS" and "CONS". Autoimmun Rev Oct 2011, 22. [epub ahead of print].
16. Pengo V., Banzato A., Denas G., Padayattil J.S., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12(8):832-834.
17. Scoble T., Wijetilleka S., Khamashta M.A. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011, 10:669-673.
18. Modena V., Bianchi G., Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?. Autoimmun Rev 2013, 12(8):835-838.
19. Rat A.C., Boissier M.C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine Nov 2004, 71(6):518-524.
20. Guillemin F., Durieux S., Daures J.P., Lafuma A., Saraux A., Sibilia J., et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004, 31:1297-1304.
21. Scott D.L., Kowalczyk A. Clinical trials: tight control in early RA pays off in the long run. Nat Rev Rheumatol 2010, 6:623-624.
22. Epis O.M., Giacomelli L., Deidda S., Bruschi E., et al. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2012 Dec 3, [Epub ahead of print].
23. Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12(8):842-847.
24. Leardini G., Salaffi F., Montanelli R., Gerzeli S., Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002, 20(4):505-515.
25. Pani A. Conventional therapy of immune-mediated glomerular diseases. Autoimmun Rev 2012 Dec 3, [Epub ahead of print].
26. Ponticelli C., Zucchelli P., Passerini P., Cesana B., Locatelli F., Pasquali S., et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995, 48:1600-1604.
27. Ponticelli C., Altieri P., Scolari F., Passerini P., Roccatello D., Cesana B., et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998, 9:444-450.
28. Korbet S.M. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002, 62:2301-2310.
29. Mukhtyar C., Flossmann O., Hellmich B., Bacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis 2008, 67(7):1004-1010.
30. Barabas A.Z., Cole C.D., Graeff R.M., Lafreniere R., Weir D.M. The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev Jan 2011, 10(3):166-170.
31. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
32. Specks U., Stone J.H. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol 2011, 2011(164):65.
33. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Russo A., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 2011, 34(2):175-180.
34. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44(12):1542-1545.
35. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62(1):222-233.
36. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61(4):482-487.
37. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Baldovino S., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011, 26(12):3987-3992.
38. Remuzzi G., Chiurchiu C., Abbate M., Brusegan V., Bontempelli M., Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002, 360(9337):923-924.
39. Fervenza F.C., Cosio F.G., Erickson S.B., Specks U., Herzenberg A.M., Dillon J.J., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008, 73(1):117-125.
40. Roccatello D., Baldovino S., Rossi D., Giachino O., Mansouri M., Naretto C., et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008, 34(1):111-117.
41. De Vita S., Quartuccio L., Isola M., Mazzaro C., Scaini P., Lenzi M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64(3):843-853.
42. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11(1):48-55.
43. Kattah A.G., Fervenza F.C., Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013, 12(8):854-859.
44. Leah E. Rituximab for refractory SLE patients reach lasting remission with short-term regimen. Nat Rev Rheumatol 2011, 7:312. http://dx.doi.org/10.1038/nrrheum, 2011.56.